DMD and Becker muscular dystrophy: As several dystrophin restoring therapies are currently in clinical trials today, with both microdystrophin therapies and exon skipping therapies having gained accelerated FDA approval in recent years, we sought to investigate whether any of the observed protein trajectories were affected by dystrophin expression in BMD patients.